Evidence map›Paper›PMID 32374912›Full record

ArticleJournal of neurochemistry2020

Acute pharmacological inhibition of matrix metalloproteinase-9 activity during development restores perineuronal net formation and normalizes auditory processing in Fmr1 KO mice.

Patricia S Pirbhoy, Maham Rais, Jonathan W Lovelace, Walker Woodard, Khaleel A Razak, Devin K Binder, Iryna M Ethell

Open access · greenAbstract read
In one paragraph

Article in Journal of neurochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Auditory processing in rodent models of autism: a systematic review.Journal of neurodevelopmental disorders · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Patricia S PirbhoyDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, USA.ORCID 0000-0001-8733-7447
Maham RaisDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, USA.
Jonathan W LovelaceDepartment of Psychology, University of California Riverside, Riverside, CA, USA.ORCID 0000-0001-5734-6801
Walker WoodardDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, USA.
Khaleel A RazakDepartment of Psychology, University of California Riverside, Riverside, CA, USA.
Devin K BinderDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, USA.
Iryna M EthellDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, USA.ORCID 0000-0002-1324-6611
University of California, Riverside · US

Funding

Neurophysiological and acute pharmacological studies in FXS patientsU54HD082008 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI HUBER, KIMBERLY M. · 2014 to 2019
$9.8M
EphB Signaling in Dendritic Spine Development and RemodelingR01MH067121 · NIMH · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI ETHELL, IRYNA M · 2003 to 2017
$4.6M
Cellular and molecular mechanisms of auditory processing deficits in a mouse model of Fragile X SyndromeF31NS117178 · NINDS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI RAIS, MAHAM · 2020 to 2021
$56k
NICHD NIH HHS U54 HD082008NIMH NIH HHS R01 MH067121NINDS NIH HHS F31 NS117178
6 · The paper itself

Abstract

Individuals with Fragile X Syndrome (FXS) and autism spectrum disorder (ASD) exhibit cognitive impairments, social deficits, increased anxiety, and sensory hyperexcitability. Previously, we showed that elevated levels of matrix metalloproteinase-9 (MMP-9) may contribute to abnormal development of parvalbumin (PV) interneurons and perineuronal nets (PNNs) in the developing auditory cortex (AC) of Fmr1 knock-out (KO) mice, which likely underlie auditory hypersensitivity. Thus, MMP-9 may serve as a potential target for treatment of auditory hypersensitivity in FXS. Here, we used the MMP-2/9 inhibitor, SB-3CT, to pharmacologically inhibit MMP-9 activity during a specific developmental period and to test whether inhibition of MMP-9 activity reverses neural oscillation deficits and behavioral impairments by enhancing PNN formation around PV cells in Fmr1 KO mice. Electroencephalography (EEG) was used to measure resting state and sound-evoked electrocortical activity in auditory and frontal cortices of postnatal day (P)22-23 male mice before and one-day after treatment with SB-3CT (25 mg/kg) or vehicle. At P27-28, animal behaviors were tested to measure the effects of the treatment on anxiety and hyperactivity. Results show that acute inhibition of MMP-9 activity improved evoked synchronization to auditory stimuli and ameliorated mouse behavioral deficits. MMP-9 inhibition enhanced PNN formation, increased PV levels and TrkB phosphorylation yet reduced Akt phosphorylation in the AC of Fmr1 KO mice. Our results show that MMP-9 inhibition during early postnatal development is beneficial in reducing some auditory processing deficits in the FXS mouse model and may serve as a candidate therapeutic for reversing sensory hypersensitivity in FXS and possibly other ASDs.

Indexed as

Acoustic StimulationAnimalsAnimals, NewbornAuditory CortexAuditory PerceptionElectroencephalographyEnzyme InhibitorsFragile X Messenger Ribonucleoprotein 1Heterocyclic Compounds, 1-RingMaleMatrix Metalloproteinase 9MiceMice, Inbred C57BLMice, KnockoutNerve NetPeripheral NervesEnzyme InhibitorsFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1Heterocyclic Compounds, 1-RingMatrix Metalloproteinase 9Mmp9 protein, mouseSB 3CT compoundSulfoneselectroencephalographyfragile X syndromematrix metalloproteinase-9parvalbuminperineuronal netssensory hypersensitivity

Identifiers

PMID32374912
PMCPMC7644613
OpenAlexW3022893014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.